Physician profile
Daniel D Dees
NPI 1700066677
$798,522.57
in general payments reported to CMS, 2019-2025
67 companies · $257K in 2025
The $257K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161K · 2020: $23K · 2021: $47K · 2022: $99K · 2023: $108K · 2024: $103K · 2025: $257K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $299K · Travel and Lodging: $56K · Honoraria: $46K · Consulting Fee: $46K · Food and Beverage: $21K · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $299,073.63 |
| Travel and Lodging | $56,079.59 |
| Honoraria | $45,940.00 |
| Consulting Fee | $45,845.92 |
| Food and Beverage | $20,720.59 |
| Education | $139.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $366,247.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $133,042.46 | 2019-2025 | Apokyn, Apokyn, Gocovri |
| Neurocrine Biosciences, INC. | $87,518.40 | 2019-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $64,732.55 | 2022-2024 | Nourianz |
| Abbvie INC. | $54,655.85 | 2019-2025 | Duopa, Botox, Qulipta |
| Acadia Pharmaceuticals INC | $30,241.59 | 2019-2025 | Nuplazid, Daybue |
| Acorda Therapeutics, INC | $28,444.06 | 2019-2024 | Inbrija |
| Lundbeck LLC | $12,432.31 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $5,740.92 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $5,206.49 | 2019-2025 | Rytary, Crexont |
| Abbott Laboratories | $1,347.22 | 2019-2025 | Infinity |
| Ucb, INC. | $1,067.37 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Boston Scientific Corporation | $613.90 | 2019-2024 | Vercise |
| Alexion Pharmaceuticals, INC. | $582.13 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $484.32 | 2019-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $434.08 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Medtronic USA, INC. | $421.85 | 2019-2020 | |
| Medtronic, INC. | $390.96 | 2021-2025 | Percept Pc Brainsense, Sensight, Activa Pc |
| Ipsen Biopharmaceuticals, INC | $389.02 | 2019-2025 | Dysport |
| Biogen, INC. | $328.27 | 2019-2025 | Skyclarys, Tysabri, Spinraza |
| Novartis Pharmaceuticals Corporation | $285.27 | 2019-2025 | |
| Amgen INC. | $283.27 | 2020-2025 | Uplizna, Aimovig |
| Merz North America, INC. | $283.22 | 2019 | |
| Allergan, INC. | $254.46 | 2019-2022 | |
| Genentech USA, INC. | $245.27 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $235.88 | 2019-2022 | |
| Lilly USA, LLC | $195.69 | 2019-2023 | Amyvid |
| Jazz Pharmaceuticals INC. | $160.78 | 2023-2025 | Epidiolex |
| Emd Serono, INC. | $149.42 | 2019-2025 | |
| Argenx US, INC. | $146.55 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $128.06 | 2021-2024 | |
| Sk Life Science, INC. | $121.56 | 2020-2025 | |
| Revance Therapeutics, INC. | $116.57 | 2024 | Daxxify |
| Pfizer INC. | $116.12 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $115.92 | 2023-2025 | Amvuttra |
| Neurelis, INC. | $111.36 | 2022-2024 | Valtoco |
| Horizon Therapeutics Plc | $99.98 | 2022-2023 | Uplizna |
| Adamas Pharmaceuticals, INC. | $96.56 | 2019-2020 | |
| Ceribell, INC. | $91.73 | 2025 | Pocket Eeg Device |
| Takeda Pharmaceuticals U.S.A., INC. | $76.70 | 2023-2025 | Hyqvia, Gammagard |
| Octapharma USA, INC. | $76.67 | 2023 | Panzyga |
| Greenwich Biosciences, INC. | $73.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $57.95 | 2023-2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $46.45 | 2022-2024 | Zonisade |
| Pyros Pharmaceuticals, INC. | $44.59 | 2024 | Vigpoder |
| Grifols USA, LLC | $44.46 | 2023-2024 | Gamunex-C |
| Sumitomo Pharma America, INC. | $42.39 | 2024 | Aptiom |
| Upsher-Smith Laboratories LLC | $40.22 | 2025 | |
| Intrabio INC | $39.51 | 2025 | Aqneursa |
| Csl Behring | $38.44 | 2024 | Hizentra |
| Zogenix INC. | $34.13 | 2021 | |
| Supernus Pharmaceuticals, INC. | $32.40 | 2019-2020 | |
| Baxter Healthcare | $31.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $29.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.10 | 2021-2022 | |
| Immedica Pharma US, INC. | $27.00 | 2024 | |
| Tg Therapeutics, INC. | $24.28 | 2025 | |
| Corium, LLC | $23.72 | 2023 | Azstarys |
| Janssen Biotech, INC. | $21.95 | 2025 | |
| Mallinckrodt Hospital Products INC. | $20.03 | 2025 | Acthar |
| Akcea Therapeutics, INC. | $19.48 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $19.32 | 2025 | Wainua |
| Chiesi USA, INC. | $16.31 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.12 | 2022 | |
| Celgene Corporation | $14.98 | 2023 | Zeposia |
| Shire North American Group INC | $13.67 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.